PharmGKB summary: cyclosporine and tacrolimus pathways.
作者信息
Barbarino Julia M, Staatz Christine E, Venkataramanan Raman, Klein Teri E, Altman Russ B
机构信息
Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDepartment of Pharmaceutical Sciences, School of Pharmacy dDepartment of Pathology, School of Medicine, Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA eSchool of Pharmacy, University of Queensland, Brisbane, Australia.
出版信息
Pharmacogenet Genomics. 2013 Oct;23(10):563-85. doi: 10.1097/FPC.0b013e328364db84.
Abstract
摘要
相似文献
1
PharmGKB summary: cyclosporine and tacrolimus pathways.药物基因组学知识库总结：环孢素和他克莫司途径。
Pharmacogenet Genomics. 2013 Oct;23(10):563-85. doi: 10.1097/FPC.0b013e328364db84.
2
ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications.ATP结合盒转运蛋白与钙调神经磷酸酶抑制剂：潜在的临床意义。
Transplant Proc. 2001 May;33(3):2420-1. doi: 10.1016/s0041-1345(01)02059-0.
3
Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child.一名肾移植儿童中环孢素与氨氯地平之间的药代动力学相互作用
Transplantation. 2012 Apr 15;93(7):e29-30. doi: 10.1097/TP.0b013e318249b180.
4
[Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].基于药代动力学和药效学分析的免疫抑制药物个体化给药方案
Yakugaku Zasshi. 2007 Jul;127(7):1081-9. doi: 10.1248/yakushi.127.1081.
5
Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.韩国实体器官移植受者中他克莫司浓度与CYP3A和ABCB1基因多态性的关系。
Transplantation. 2009 Apr 27;87(8):1225-31. doi: 10.1097/TP.0b013e31819f117e.
6
Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.影响韩国肾移植受者他克莫司谷浓度和药物相关结局的临床和遗传因素。
Eur J Clin Pharmacol. 2012 May;68(5):657-69. doi: 10.1007/s00228-011-1182-5. Epub 2011 Dec 20.
7
Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation.免疫抑制剂在儿科器官移植中的发育药理学。
Ther Drug Monit. 2010 Dec;32(6):688-99. doi: 10.1097/FTD.0b013e3181f6502d.
8
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.CYP3A 和 ABCB1 单核苷酸多态性对钙调神经磷酸酶抑制剂的药代动力学和药效学的影响：第一部分。
Clin Pharmacokinet. 2010 Mar;49(3):141-75. doi: 10.2165/11317350-000000000-00000.
9
[Cytochrome P450 3A polymorphism and its importance in cyclosporine and tacrolimus therapy in transplanted patients].[细胞色素P450 3A多态性及其在移植患者环孢素和他克莫司治疗中的重要性]
Ceska Slov Farm. 2007 Oct;56(5):220-4.
10
Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.肝、肾移植患者中环孢素剂量优化的药物遗传学考虑因素。
World J Gastroenterol. 2013 Dec 28;19(48):9156-73. doi: 10.3748/wjg.v19.i48.9156.
引用本文的文献
1
Polymorphisms in , and genes: implications for calcineurin inhibitors therapy in hematopoietic cell transplantation recipients-a systematic review.、和基因的多态性：对造血细胞移植受者钙调神经磷酸酶抑制剂治疗的影响——一项系统综述
Front Pharmacol. 2025 Jul 16;16:1569353. doi: 10.3389/fphar.2025.1569353. eCollection 2025.
2
The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients.CYP3A4、CYP3A5和MDR1（ABCB1）单核苷酸多态性对阿尔及利亚稳定肾移植受者中环孢素药代动力学的影响。
Mol Biol Rep. 2025 Jul 25;52(1):756. doi: 10.1007/s11033-025-10862-z.
3
Hazardous Interactions Between Food, Herbs, and Drugs in the First Stage of Biotransformation: Case Reports of Adverse Drug Interactions in Humans.生物转化第一阶段中食物、草药与药物之间的有害相互作用：人类药物不良相互作用的病例报告
Int J Mol Sci. 2025 May 28;26(11):5188. doi: 10.3390/ijms26115188.
4
Optimal GVHD Prophylaxis.最佳移植物抗宿主病预防措施
Adv Exp Med Biol. 2025;1475:77-102. doi: 10.1007/978-3-031-84988-6_5.
5
Establishment of interpretable cytotoxicity prediction models using machine learning analysis of transcriptome features.利用转录组特征的机器学习分析建立可解释的细胞毒性预测模型。
Acta Pharm Sin B. 2025 Mar;15(3):1344-1358. doi: 10.1016/j.apsb.2025.02.009. Epub 2025 Feb 12.
6
Survey of the utilization of genotype-guided tacrolimus management in United States solid organ transplant centers.美国实体器官移植中心基因型指导下他克莫司管理的应用调查。
Pharmacogenomics. 2025 Feb-Mar;26(3-4):89-94. doi: 10.1080/14622416.2025.2489920. Epub 2025 Apr 9.
7
Providing care for kidney transplant recipients: An overview for generalists.为肾移植受者提供护理：全科医生概述
World J Nephrol. 2025 Mar 25;14(1):99555. doi: 10.5527/wjn.v14.i1.99555.
8
Effect of hypoalbuminemia on drug pharmacokinetics.低白蛋白血症对药物药代动力学的影响。
Front Pharmacol. 2025 Feb 20;16:1546465. doi: 10.3389/fphar.2025.1546465. eCollection 2025.
9
Promoter Polymorphism (Allelic Variation) Affects Tacrolimus Treatment Efficacy by Modulating E2F6 Binding Affinity.启动子多态性（等位基因变异）通过调节E2F6结合亲和力影响他克莫司治疗效果。
Biomedicines. 2024 Dec 19;12(12):2896. doi: 10.3390/biomedicines12122896.
10
Engineering immunity with nanoparticles: highlights from recent research on transplant rejection therapy.用纳米颗粒构建免疫：近期移植排斥治疗研究亮点
Nanomedicine (Lond). 2025 Feb;20(4):339-342. doi: 10.1080/17435889.2024.2443386. Epub 2024 Dec 18.
本文引用的文献
1
Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.CYP3A5、CYP3A4和ABCB1基因作为心脏移植后他克莫司剂量及临床结局决定因素的作用
Transplant Proc. 2012 Nov;44(9):2635-8. doi: 10.1016/j.transproceed.2012.09.062.
2
Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.P450 氧化还原酶 28 多态性对中国健康男性志愿者他克莫司药代动力学的影响。
Eur J Clin Pharmacol. 2013 Apr;69(4):807-12. doi: 10.1007/s00228-012-1432-1. Epub 2012 Oct 25.
3
NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation.NR1I2 多态性与成人肾移植中环孢素调整剂量后的暴露和 BK 病毒血症有关。
Transplantation. 2012 Nov 27;94(10):1025-32. doi: 10.1097/TP.0b013e31826c3985.
4
Donor ABCB1 variant associates with increased risk for kidney allograft failure.供体 ABCB1 变异与肾移植失败风险增加相关。
J Am Soc Nephrol. 2012 Nov;23(11):1891-9. doi: 10.1681/ASN.2012030260. Epub 2012 Oct 11.
5
Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.CYP3A4*1B和CYP3A5*3基因多态性对肾移植受者中环孢素和西罗莫司药代动力学的影响。
Ann Transplant. 2012 Jul-Sep;17(3):36-44. doi: 10.12659/aot.883456.
6
Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.肝肠 CYP3A5 基因型组合对活体肝移植受者他克莫司药代动力学的影响。
Transplantation. 2012 Oct 27;94(8):866-72. doi: 10.1097/TP.0b013e318263700a.
7
ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.ABCB1 多态性与肾移植受者环孢素诱导的肾毒性和牙龈增生有关。
Eur J Clin Pharmacol. 2013 Mar;69(3):385-93. doi: 10.1007/s00228-012-1355-x. Epub 2012 Aug 11.
8
In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.在体内 CYP3A4 活性、CYP3A5 基因型和红细胞压积可预测肾移植患者他克莫司的剂量需求和清除率。
Clin Pharmacol Ther. 2012 Sep;92(3):366-75. doi: 10.1038/clpt.2012.109. Epub 2012 Aug 8.
9
The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis.CYP3A5 6986A>G 和 ABCB1 3435C>T 对肾移植受者他克莫司剂量调整谷浓度和急性排斥反应率的影响：系统评价和荟萃分析。
Pharmacogenet Genomics. 2012 Aug;22(8):642-5. doi: 10.1097/FPC.0b013e3283557c74.
10
The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients.新的 CYP3A4 内含子 6 C>T 多态性（CYP3A4*22）与环孢素治疗的肾移植患者发生延迟移植物功能和肾功能恶化的风险增加相关。
Pharmacogenet Genomics. 2012 May;22(5):373-80. doi: 10.1097/FPC.0b013e328351f3c1.
Zotero 插件